*nlm.life
			PubMed Journals: J Clin Med

  Source:		PMID: 32110875


    		J Clin Med. 2020 Feb 26;9(3). pii: E623. doi:
     		10.3390/jcm9030623.

			Potential Rapid Diagnostics, Vaccine and
			Therapeutics for 2019 Novel Coronavirus
			(2019-nCoV): A Systematic Review.

			Pang J(1)(2), Wang MX(1)(2), Ang IYH(1), Tan
			SHX(1), Lewis RF(1), Chen JI(1), Gutierrez
			RA(3), Gwee SXW(1)(2), Chua PEY(1)(2), Yang
			Q(1), Ng XY(1), Yap RK(1), Tan HY(1), Teo
			YY(1), Tan CC(4), Cook AR(1), Yap JC(1), Hsu
			LY(1).

			Author Information
			(1) Saw Swee Hock School of Public Health,
			National University of Singapore and
			National University Health System, Singapore
			117549, Singapore.
			(2) Centre for Infectious Disease Epidemiology
			and Research, National University of Singapore,
			Singapore 117549, Singapore.
			(3) National Centre for Infectious Diseases,
			Singapore 308442, Singapore.
			(4) Ministry of Health, Singapore 169854,
			Singapore.

			Rapid diagnostics, vaccines and therapeutics
			are important interventions for the management
			of the 2019 novel coronavirus (2019-nCoV)
			outbreak. It is timely to systematically review
			the potential of these interventions, including
			those for
			Middle East respiratory syndrome-Coronavirus
			(MERS-CoV) and
			severe acute respiratory syndrome
			(SARS)-CoV, to guide policymakers globally on
			their prioritization of resources for research and
			development. A systematic search was carried
			out in three major electronic databases
			(PubMed, Embase and Cochrane Library) to
			identify published studies in accordance with
			the Preferred Reporting Items for Systematic
			Reviews and Meta-Analyses (PRISMA)
			guidelines. Supplementary strategies through
			Google Search and personal communications
			were used. A total of 27 studies fulfilled the
			criteria for review. Several laboratory protocols
			for confirmation of suspected 2019-nCoV
			cases using real-time reverse transcription
			polymerase chain reaction (RT-PCR) have been
			published. A commercial RT-PCR kit developed
			by the Beijing Genomic Institute is currently
			widely used in China and likely in Asia.
			However, serological assays as well as
			point-of-care testing kits have not been
			developed but are likely in the near future.
			Several vaccine candidates are in the pipeline.
			The likely earliest Phase 1 vaccine trial is a
			synthetic DNA-based candidate. A number of
			novel compounds as well as therapeutics
			licensed for other conditions appear to have in
			vitro efficacy against the 2019-nCoV. Some are
			being tested in clinical trials against MERS-CoV
			and SARS-CoV, while others have been listed
			for clinical trials against 2019-nCoV. However,
			there are currently no effective specific antivirals
			or drug combinations supported by high-level
			evidence.

			DOI: 10.3390/jcm9030623 PMID: 32110875

			Conflict of interest statement: The authors
			declare no conflict of interest.

     			                         Tweet       Print